Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Pharmaceutics 2014, 6(1), 137-174; doi:10.3390/pharmaceutics6010137
Review

Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology

1,* , 1
 and 1,2
Received: 14 January 2014; in revised form: 22 February 2014 / Accepted: 26 February 2014 / Published: 18 March 2014
(This article belongs to the Special Issue Liposome Technologies)
View Full-Text   |   Download PDF [1169 KB, uploaded 18 March 2014]   |   Browse Figures
Abstract: Liposomal formulations of anticancer agents have been developed to prolong drug circulating lifetime, enhance anti-tumor efficacy by increasing tumor drug deposition, and reduce drug toxicity by avoiding critical normal tissues. Despite the clinical approval of numerous liposome-based chemotherapeutics, challenges remain in the development and clinical deployment of micro- and nano-particulate formulations, as well as combining these novel agents with conventional drugs and standard-of-care therapies. Factors requiring optimization include control of drug biodistribution, release rates of the encapsulated drug, and uptake by target cells. Quantitative mathematical modeling of formulation performance can provide an important tool for understanding drug transport, uptake, and disposition processes, as well as their role in therapeutic outcomes. This review identifies several relevant pharmacokinetic/pharmacodynamic models that incorporate key physical, biochemical, and physiological processes involved in delivery of oncology drugs by liposomal formulations. They capture observed data, lend insight into factors determining overall antitumor response, and in some cases, predict conditions for optimizing chemotherapy combinations that include nanoparticulate drug carriers.
Keywords: liposomes; nanoparticulate drug carriers; drug delivery; pharmacokinetics; pharmacodynamics; mathematical simulation liposomes; nanoparticulate drug carriers; drug delivery; pharmacokinetics; pharmacodynamics; mathematical simulation
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Ait-Oudhia, S.; Mager, D.E.; Straubinger, R.M. Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology. Pharmaceutics 2014, 6, 137-174.

AMA Style

Ait-Oudhia S, Mager DE, Straubinger RM. Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology. Pharmaceutics. 2014; 6(1):137-174.

Chicago/Turabian Style

Ait-Oudhia, Sihem; Mager, Donald E.; Straubinger, Robert M. 2014. "Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology." Pharmaceutics 6, no. 1: 137-174.



Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert